Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAF(V600E) metastatic melanoma. However, resistance to such compounds represents a formidable problem. Using whole-exome sequencing and functional analyses, we have investigated the nature and ple...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemper, Kristel, Krijgsman, Oscar, Cornelissen-Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, Song, Ji-Ying, Kuilman, Thomas, Vis, Daniel J, Wessels, Lodewyk F, Voest, Emile E, Schumacher, Ton NM, Blank, Christian U, Adams, David J, Haanen, John B, Peeper, Daniel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568946/
https://www.ncbi.nlm.nih.gov/pubmed/26105199
http://dx.doi.org/10.15252/emmm.201404914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568946/
https://www.ncbi.nlm.nih.gov/pubmed/26105199
http://dx.doi.org/10.15252/emmm.201404914

Ejemplares similares